Company / Cash & Equivalents
Outset Medical, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$35.0M
FY2025
5-year range
$35.0M / $295.0M
FY2021-FY2025
Trend
-71.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 6 years, ranging from $35M in FY2025 to $295M in FY2021.
Based on SEC 10-K filings.
$35M in FY2025 with a 5-year CAGR of -1.1%.
Declined from $69M to $35M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -42.3%
- 5-Year CAGR
- -1.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.1%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 71.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.88 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.0M | -71.8% |
| FY2024 | $124.0M | +81.0% |
| FY2023 | $68.5M | -62.4% |
| FY2022 | $182.3M | -38.2% |
| FY2021 | $295.0M | +698.8% |
| FY2020 | $36.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026